Accéder au contenu
Merck
Toutes les photos(1)

Documents

860506P

Avanti

C6 Ceramide (d18:1/6:0)

Avanti Research™ - A Croda Brand

Synonyme(s) :

N-hexanoyl-D-erythro-sphingosine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C24H47NO3
Numéro CAS:
124753-97-5
Poids moléculaire :
397.63
Code UNSPSC :
12352211
Nomenclature NACRES :
NA.25

Forme

powder

Conditionnement

pkg of 1 × 10 mg (860506P-10mg)
pkg of 1 × 5 mg (860506P-5mg)

Fabricant/nom de marque

Avanti Research™ - A Croda Brand

Type de lipide

sphingolipids

Conditions d'expédition

dry ice

Température de stockage

−20°C

Chaîne SMILES 

OC[C@]([H])(NC(CCCCC)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC

InChI

1S/C24H47NO3/c1-3-5-7-8-9-10-11-12-13-14-15-16-18-19-23(27)22(21-26)25-24(28)20-17-6-4-2/h18-19,22-23,26-27H,3-17,20-21H2,1-2H3,(H,25,28)/b19-18+

Clé InChI

NPRJSFWNFTXXQC-VHEBQXMUSA-N

Catégories apparentées

Description générale

C6 Ceramide (d18:1/6:0) is a short chain and a cell permeable ceramide. It comprises amino alcoholic chain attached to fatty acyl chain via an amide linkage.

Application

C6 Ceramide (d18:1/6:0) has been used as a chemotherapeutic agent to test its anti-tumor effect in breast cancer cells and ovarian cancer cell lines. It has also been used to test chemo-sensitization effects in cancer cells.

Actions biochimiques/physiologiques

C6 Ceramide (d18:1/6:0) is involved in inhibiting proliferation and inducing apoptosis. When used in combination with acid ceramidase inhibitor DM102, [(2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl)pivaloylamide], it favors cell death in human breast cancer cells lines. C6 Ceramide may serve as an adjunct in chemotherapy. It elicits anti-tumor effects via AKT (serine/threonine-specific protein kinase) dephosphorylation and α-tubulin acetylation.

Conditionnement

5 mL Amber Glass Screw Cap Vial (860506P-10mg)
5 mL Amber Glass Screw Cap Vial (860506P-5mg)

Informations légales

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Souvent commandé avec ce produit

Réf. du produit
Description
Tarif

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 5

1 of 5

C18 Ceramide (d18:1/18:0) Avanti Research™ - A Croda Brand

Avanti

860518P

C18 Ceramide (d18:1/18:0)

Ceramide (Brain) Ceramide (Brain, Porcine), powder

Avanti

860052P

Ceramide (Brain)

06:0 SM (d18:1/6:0) Avanti Research™ - A Croda Brand 860582C

Avanti

860582C

06:0 SM (d18:1/6:0)

C12-NBD Ceramide Avanti Research™ - A Croda Brand 810211P, powder

Avanti

810211P

C12-NBD Ceramide

Ceramide from bovine spinal cord ≥98.0% (TLC)

Sigma-Aldrich

22244

Ceramide from bovine spinal cord

C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth
Flowers M, et al.
Breast Cancer Research and Treatment, 133(2), 447-458 (2012)
Q-y Zhu et al.
Cell death & disease, 2, e117-e117 (2011-03-04)
Histone deacetylase inhibitors (HDACIs) have shown promising anti-tumor effects for a variety of malignancies, however, many tumors are reportedly resistant to them. In this study, we made a novel discovery that co-administration of HDACIs (Trichostatin A (TSA) and others) and
C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study
Yang L, et al.
Experimental Cell Research, 332(1), 47-59 (2015)
Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition
Ji C, et al.
Oncogene, 29(50), 6557-6557 (2010)
C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo
Zhu QY, et al.
Cell Death & Disease, 2(1), e117-e117 (2011)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique